JANX Stock Analysis: Buy, Sell, or Hold?
JANX - Janux Therapeutics, Inc. Common Stock
$13.81
0.14 (1.06%)
▲
5d:
+3.33%
30d:
-5.51%
90d:
+1.66%
BUY
MODERATE Confidence
Analysis Updated: Jun 11, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When JANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JANX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: JANX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: JANX is currently trading at $13.80, which is considered slightly low relative to its 30-day fair value range of $13.70 to $14.55.
Technical Outlook: Technically, JANX is in a uptrend. Immediate support is located at $12.98, while resistance sits at $14.79.
Market Sentiment: JANX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.56 (+196.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JANX is in a uptrend. Immediate support is located at $12.98, while resistance sits at $14.79.
Market Sentiment: JANX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $40.56 (+196.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$13.70 -
$14.55
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 196.9% below Wall St target ($40.56)
Trading Range Analysis
30-Day Trading Range
$13.70 -
$14.55
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.05
(7.6%)
Support & Resistance Levels
Support Level
$12.99
Resistance Level
$14.79
Current Trend
Uptrend
Technical data as of
Jun 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.93
Wall Street Target
$40.56
(+196.9%)
Revenue Growth (YoY)
2177.9%
Share & Embed Analysis
Last updated: June 12, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:37 PM
Data refreshes hourly during market hours. Next update: 12:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew Hollman Meyer
SELL
1879 shares
2026-01-02
Charles M Winter
SELL
2401 shares
2026-01-02
David Alan Campbell
SELL
8072 shares
2026-01-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$253 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 52 HOLD |
